within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J07B_ViralVaccines.J07BM02_PapillomavirusHumanTypes;

model PapillomavirusHumanTypes
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 0,
    adminDuration = 600,
    adminMass = 0.5 / 1000000,
    adminCount = 1,
    Vd = 0.001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>PapillomavirusHumanTypes1618</td></tr><tr><td>ATC code:</td><td>J07BM02</td></tr><td>route:</td><td>intramuscular</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>0.5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Papillomavirus (human types 16, 18) vaccine, commonly known as HPV vaccine, is used for active immunization against diseases caused by human papillomavirus types 16 and 18, including cervical cancer and other HPV-related cancers. It is an approved and widely used prophylactic vaccine.</p><h4>Pharmacokinetics</h4><p>No conventional pharmacokinetic parameters are reported for this vaccine, as it is a recombinant protein subunit vaccine administered intramuscularly. No peer-reviewed publication has reported classical PK parameters such as volume of distribution or clearance.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J07BM02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end PapillomavirusHumanTypes;
